SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-012575
Filing Date
2022-03-15
Accepted
2022-03-15 16:30:11
Documents
14
Period of Report
2022-03-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea156911-8k_virpaxpharma.htm   iXBRL 8-K 27372
2 PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC. ISSUED MARCH 15, 2022 ea156911ex99-1_virpaxpharma.htm EX-99.1 15114
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2535
  Complete submission text file 0001213900-22-012575.txt   227619

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE vrpx-20220315.xsd EX-101.SCH 3045
5 XBRL LABEL FILE vrpx-20220315_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE vrpx-20220315_pre.xml EX-101.PRE 22603
8 EXTRACTED XBRL INSTANCE DOCUMENT ea156911-8k_virpaxpharma_htm.xml XML 3722
Mailing Address 1554 PAOLI PIKE #279 WEST CHESTER PA 19380
Business Address 1554 PAOLI PIKE #279 WEST CHESTER PA 19380 484-875-3195
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 22741527
SIC: 2834 Pharmaceutical Preparations